Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer

Table 1 Frequency of CpG island methylator phenotype-high in colorectal cancers: A review of the literature

Ref.	Country	CIMP-H CRCs/tested CRCs n (%)
		In all CRCs	In MSI-H CRCs
Western countries
Samowitz et al[22], 2005	United States	250/859 (29.1)	64/78 (82.1)
Weisenberger et al[13], 2006	United States	33/187 (17.6)	NA
Samowitz et al[84], 2006	United States	313/1271 (24.6)	105/170 (61.8)
Barault et al[85], 2008	France	95/578 (16.4)	58/80 (72.5)
Ogino et al[4], 2009	United States	123/631 (19.5)	86/118 (72.9)
Dahlin et al[86], 2010	Sweden	46/411 (11.2)	34/61 (55.7)
Zlobec et al[24], 2011	Switzerland	22/314 (7)	NA
Lochhead et al[63], 2013	United States	205/1173 (17.5)	140/184 (76.1)
Eastern countries
Koinuma et al[101], 2004	Japan	NA	161/28 (57.1)
Nagasaka et al[102], 2008	Japan and Germany	NA	152/36 (41.7)
Kim et al[98], 2009	South Korea	29/271 (10.7)	8/33 (24.2)
Min et al[99], 2011	South Korea	34/245 (13.9)	NA
Bae et al[97], 2013	South Korea	47/734 (6.4)	18/65 (27.7)
Kim et al[25], 2013	South Korea	NA	64/220 (29.1)

¹MLH1-methylated colorectal cancers (CRCs) instead of CpG island methylator phenotype-high (CIMP-H) CRCs;

²Sporadic microsatellite instability-high (MSI-H) CRCs instead of CIMP-H CRCs. NA: Not applicable.